Celularity Inc (CELU) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Celularity Inc $1.89, price $1.56, upside +21.0%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range $0.5979 – $129.10 · fair‑value band $1.11 – $2.49 · the $1.56 price screens below the $1.89 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Celularity in your weekly email
Every Wednesday you see whether Celularity is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Show more
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Stock analysis
Celularity Inc (CELU) currently trades at $1.56, while our model-based Fair Value estimate is $1.89, implying the stock looks roughly 17.3% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $1.11 (bear) to $2.49 (bull), the price of $1.56 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Celularity Inc reported revenue of $26.6M in FY2025 versus $21.3M in FY2021, a compound +5.6%/yr. Reported net income was −$91.8M in FY2025.
Key figures
Market cap $51.9M · P/S ratio 2.74 · EPS (TTM) $−3.16 · Dividend yield 11.4% · Return on equity −6,367% · Return on assets (EBIT) −34.4% · Operating margin −263% · Revenue (TTM) $19.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and 161% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 21%, CELU screens cheaper than that median.
Fair Value models
Bear $1.11Fair Value $1.89Bull $2.49
Price $1.56 · Upside +21.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−51.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,064.0% (2020) → −230.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 587 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score22 · Bottom 25%
Fair Value upside+21.0% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−32.3% · Bottom 25%
Growth and dividend
Revenue growth−66.3% · Bottom 25%
Dividend yield (TTM)11.4% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)2.74× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)61· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)100· sector 22
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Celularity Inc Fair Value". https://www.fairvalue-calculator.com/stock/CELU
Frequently asked questions
Is Celularity Inc (CELU) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $1.89 versus a price of $1.56, about +21% upside (undervalued).
What is the fair value of CELU?
Our model-based fair value for Celularity Inc is $1.89 (as of Oct 4, 2026), built from audited fundamentals. The current price: $1.56.
What is the quality score of CELU?
Celularity Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Celularity Inc (CELU)?
Our model-based price target is the fair value of $1.89 (as of Oct 4, 2026) from 2 valuation models. Cautious scenario $1.11, optimistic scenario $2.49. It is a calculation from audited fundamentals, not an analyst target.
What is the Celularity Inc stock forecast for 2026?
Our models put fair value at $1.89, about +21% upside versus a price of $1.56 (undervalued). Cautious scenario $1.11, optimistic scenario $2.49. The calculation is refreshed regularly with new filings.
What is the revenue of Celularity Inc (CELU)?
Celularity Inc reported trailing-twelve-month revenue of about $19.0M (latest available figure, as of Oct 4, 2026).
Does Celularity Inc pay a dividend?
Celularity Inc currently shows a dividend yield of about 11.36% relative to its recent price (as of Oct 4, 2026).
What is the intrinsic value of Celularity Inc (CELU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Celularity Inc it is $1.89 per share (as of Oct 4, 2026), against a price of $1.56. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Celularity Inc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, CELU trades below its calculated fair value: price $1.56, fair value $1.89, a gap of about +21% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CELU?
No. The price is what the market pays today ($1.56); the fair value is what the company's own numbers justify ($1.89). For Celularity Inc the two are $0.3270 per share apart. That gap is exactly why we show both numbers side by side.
How much is Celularity Inc worth?
The market values Celularity Inc at about $51.9M (market capitalisation, as of Oct 4, 2026). Per share that is $1.56; our models calculate a fair value of $1.89 per share.
What do the bullish and bearish scenarios say about CELU?
Our models span a range for Celularity Inc: cautious scenario $1.11, base $1.89, optimistic $2.49 per share (as of Oct 4, 2026, price $1.56). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Celularity Inc (CELU)?
Balance-sheet figures for Celularity Inc (as of Oct 4, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is CELU from its 52-week high?
Celularity Inc trades at $1.56, about 31% below its 52-week high of $2.27 and 161% above the low of $0.5979 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of $1.89 is for.
Which stocks are comparable to Celularity Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Celularity Inc stock attractive at the current price?
The data as of Oct 4, 2026: price $1.56, calculated fair value $1.89 (+21%), Quality Score 22/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CELU calculated?
We run Celularity Inc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.89, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Celularity Inc currently trades 17 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Celularity Inc (CELU)?
The closing price on Oct 9, 2026 was $1.56. Our model-based fair value is $1.89, about +21% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Celularity Inc right now?
A fairly wide model range ($1.11 to $2.49) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Celularity Inc
How large is the market capitalisation of Celularity Inc (CELU)?
The market capitalisation of Celularity Inc is $51.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Celularity Inc (CELU)?
The price-to-sales ratio of Celularity Inc is 2.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Celularity Inc (CELU)?
Earnings per share at Celularity Inc are $−3.16. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Celularity Inc (CELU)?
The dividend yield of Celularity Inc is 11.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of Celularity Inc (CELU)?
The return on equity (ROE) of Celularity Inc is −6,367% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Celularity Inc (CELU)?
On an EBIT basis the return on assets of Celularity Inc is −34.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Celularity Inc (CELU)?
The operating margin of Celularity Inc is −263% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Celularity Inc (CELU)?
Revenue at Celularity Inc is growing −66.3% versus a year earlier (3y avg +13.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Celularity Inc (CELU)?
Earnings per share at Celularity Inc are growing −61.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Celularity Inc (CELU) generate?
The free cash flow of Celularity Inc is −$13.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Celularity Inc (CELU) carry?
The net debt of Celularity Inc is $34.7M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Celularity Inc in the live analysis
One click puts Celularity Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 4, 2026